EGFR and lung carcinoma: EGFR is frequently overexpressed in approximately 40–80% of NSCLC tumors; therefore, EGFR activity and/or expression is an important factor in the treatment of lung cancer that must be taken into consideration by clinicians attempting to manage the disease [38].